BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,434,444 | +278.4% | 343,848 | +276.2% | 0.01% | +300.0% |
| Q2 2023 | $643,435 | -88.5% | 91,397 | -86.4% | 0.00% | -89.3% |
| Q1 2023 | $5,615,030 | +84.4% | 673,265 | +153.9% | 0.03% | +64.7% |
| Q4 2022 | $3,044,691 | +46.9% | 265,217 | +108.0% | 0.02% | +41.7% |
| Q1 2022 | $2,073,000 | -78.4% | 127,510 | -81.6% | 0.01% | -77.4% |
| Q4 2021 | $9,610,000 | -43.3% | 693,830 | -41.2% | 0.05% | -51.4% |
| Q3 2021 | $16,961,000 | +87.4% | 1,180,297 | +106.2% | 0.11% | +73.0% |
| Q2 2021 | $9,049,000 | +16.9% | 572,378 | -44.9% | 0.06% | -3.1% |
| Q4 2020 | $7,740,000 | +7488.2% | 1,038,874 | +2814.4% | 0.06% | +3150.0% |
| Q3 2019 | $102,000 | -79.4% | 35,646 | -72.6% | 0.00% | -85.7% |
| Q2 2019 | $494,000 | +384.3% | 130,300 | +942.0% | 0.01% | +366.7% |
| Q1 2019 | $102,000 | – | 12,505 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |